Virelion
Tools Talk to us

Gene therapy

VB-101: computational prioritization of myocardial regeneration regulators.

Research bench scene illustrating cardiac gene therapy design with AAV and modified RNA concepts.
Scientific deep dive. Target classes, modality tradeoffs, myocardial delivery, temporal control, and VB-101 candidate gates are documented separately. Open scientific detail →
VB-101 Gene therapy
VB-101 discovery path from evidence assembly to shortlist and future physical testing
VB-101
Program ID
1-3
Lead target goal
2024
Discovery start
Open
Evidence trail

Scientific question

Which molecular regulators have enough independent biological support to warrant experimental testing as drivers or enablers of myocardial regeneration?

Approach

Multi-omic and published evidence, curation and QC, regeneration-associated signals, cross-dataset comparison, mechanistic assessment, prioritization.

Outcome of this phase

A documented shortlist of 1-3 leads with evidence, uncertainties, and proposed experiments. Not a validated therapeutic target list.

Links

GitHub
Discovery dossier (PDF)
Pipeline status · Protein & drug

Criteria for a strong candidate